Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. reports developments for a global healthcare company with a portfolio spanning generics, established brands and innovative medicines. News commonly covers quarterly results, guidance, cash deployment, dividends, capital allocation and management changes, alongside product launches and pipeline updates across major therapeutic areas.
Company updates also include scientific presentations and regulatory actions tied to specific medicines and candidates, including Effexor in Japan, ophthalmology programs such as phentolamine ophthalmic solution and RYZUMVI, and an investigational low-dose estrogen combined hormonal contraceptive weekly patch. Viatris was formed through the combination of Mylan and Pfizer's Upjohn business and operates with global centers in the U.S., China and India.
Viatris Inc. (NASDAQ: VTRS) will announce its second quarter 2021 financial results on August 9, before the U.S. market opens. A webcast featuring CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will be held at 10 a.m. ET the same day. Investors can listen to the call live via the company's investor website or by phone. Established in November 2020, Viatris focuses on providing access to medicines and healthcare solutions globally, maintaining a portfolio of over 1,400 approved molecules.
Viatris (NASDAQ: VTRS) will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 10:30 a.m. ET. CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will discuss the company and address queries. Interested individuals can access the live webcast at investor.viatris.com, with an archived version available later. Viatris aims to empower global health through access to over 1,400 medicines and operates in 165 countries.
Viatris Inc. (VTRS) reported Q1 2021 financial results with total revenue at $4.4 billion, reflecting a 70% increase year-over-year. The company faced a U.S. GAAP net loss of $1.0 billion, while adjusted EBITDA stood at $1.6 billion. Free cash flow reached $799 million. The Board declared a quarterly dividend of $0.11 per share, payable June 26, 2021. Viatris anticipates achieving approximately $500 million in synergies and has generated $163 million from new product revenue, reiterating its positive outlook for the year.
Summary not available.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference on May 18, 2021, at 9:10 a.m. ET. CEO Michael Goettler and CFO Sanjeev Narula will discuss the company and answer questions. A live webcast will be available at investor.viatris.com, with an archived version accessible later. Formed in November 2020 from Mylan and Pfizer's Upjohn business, Viatris serves over 165 countries and offers a diverse portfolio of over 1,400 approved medicines.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the BofA Securities 2021 Health Care Conference on May 11, 2021, at 8 a.m. ET. President Rajiv Malik and CFO Sanjeev Narula will address questions regarding the company. Interested parties can access a live webcast at investor.viatris.com, with an archived version available afterward. Viatris, formed in November 2020, aims to provide global access to a diverse portfolio of over 1,400 medicines targeting various health conditions, supporting sustainable healthcare.
Viatris Inc. (NASDAQ: VTRS) will release its first quarter 2021 financial results on May 10, 2021, prior to the U.S. market opening. A webcast will follow at 10 a.m. ET to discuss these results, accessible at investor.viatris.com or via phone at 855.493.3607. Viatris formed in November 2020, merging Mylan and Pfizer's Upjohn. The company aims to improve global health access with a portfolio of over 1,400 approved molecules and operates in over 165 countries.
On March 8, 2021, Viatris (NASDAQ: VTRS) and Kindeva Drug Delivery announced the FDA granted tentative approval for the first generic version of Symbicort, budesonide/formoterol fumarate dihydrate. This approval, however, comes amid ongoing patent litigation with AstraZeneca, preventing immediate commercial launch. Despite significant U.S. sales of Symbicort, Viatris has not projected any revenue from this product for 2021. This milestone reflects the partnership's strength and Viatris’ commitment to advancing access to respiratory treatments.
Viatris Inc. (NASDAQ: VTRS) will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on March 10, 2021, at 3:00 p.m. ET. Key executives including CEO Michael Goettler, President Rajiv Malik, and CFO Sanjeev Narula will address questions regarding the company. A live webcast can be accessed at investor.viatris.com, with an archived version available afterward. Viatris, formed in November 2020 from Mylan and Pfizer's Upjohn business, aims to enhance global healthcare access.
On March 1, 2021, Viatris Inc. (NASDAQ: VTRS) hosted its inaugural investor day, presenting its unique healthcare model aimed at enhancing shareholder value. CEO Michael Goettler emphasized a commitment to sustainability, financial stability, and growth through their Global Healthcare Gateway. Viatris expects 2021 to be a trough year, projecting $1 billion in synergies within three years and a dividend initiation in Q2 2021. The company plans to reduce $6.5 billion in debt by the end of 2023 and focus on improving free cash flow while building a diverse portfolio for global access to medicines.